This was the stock's fifth consecutive day of losses.

Bristol-Myers Squibb Company ( NYSE: BMY) is scheduled to announce Q2 earnings results on July 31st, before markets open.

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Now, it’s worth noting Stock Advisor’s total average return is 1,039% — a market-crushing outperformance compared to 182 % for the S&P 500. Don’t miss out on the latest top 10 list, available when you ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Novo Nordisk promoted Maziar Mike Doustdar to president and CEO, effective August 7. The Food and Drug Administration tapped newly appointed George Tidmarsh as acting Center for Biologics Evaluation ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

Bearish flow noted in Bristol Myers ( BMY) Squibb with 9,747 puts trading, or 1.5x expected. Most active are 8/1 weekly 46 puts and Aug-25 47 calls, with total volume in those strikes near 6,100 ...